Literature DB >> 16557868

Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.

L S Young1, B H Yu, D Armstrong.   

Abstract

The human immune response to Pseudomonas aeruginosa infection was studied by using the double diffusion in agar-gel technique. Antigens from Fisher-Devlin-Gnabasik immunotypes were prepared by both trichloroacetic acid extraction and ultrasonic disruption. Serum from 72 of 168 patients (43%) from whom P. aeruginosa was isolated formed from one to eight precipitin bands. Precipitins were demonstrated in the sera of 60 of 66 (91%) patients recovering from bacteremia and deep infections; however, they were usually absent when Pseudomonas infection was fatal or when there was no clinical evidence of significant infection. Precipitating antibody was detectable at serum dilutions as high as 1:32, and appearance of single bands correlated with hemagglutinating antibody titers of >/=1:128. Antigen from sonically disrupted organisms usually resulted in stronger precipitin bands than trichloroacetic acid extracts, and antigen from the homologous infecting strain occasionally increased test sensitivity. None of 50 normal controls had Pseudomonas precipitins as was the case in patients convalescing from Escherichia coli (15 patients), Klebsiella-Enterobacter-Serratia (18), and Proteus (14) bacteremias. Measurement of agar-gel precipitins was useful and specific in evaluating the circulating antibody response to P. aeruginosa infections.

Entities:  

Year:  1970        PMID: 16557868      PMCID: PMC416039          DOI: 10.1128/iai.2.4.495-503.1970

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  PSEUDOMONAS INFECTION. TREATMENT WITH IMMUNE PLASMA.

Authors:  D S FEINGOLD; F OSKI
Journal:  Arch Intern Med       Date:  1965-09

2.  A proposed antigenic schema for the identification of strains of Pseudomonas aeruginosa.

Authors:  E VERDER; J EVANS
Journal:  J Infect Dis       Date:  1961 Sep-Oct       Impact factor: 5.226

3.  Occurrence of serious bacterial infections since introduction of antibacterial agents.

Authors:  M FINLAND; W F JONES; M W BARNES
Journal:  J Am Med Assoc       Date:  1959-08-29

4.  Prevalence of antibody to Pseudomonas in normal human sera.

Authors:  S GAINES; M LANDY
Journal:  J Bacteriol       Date:  1955-06       Impact factor: 3.490

5.  Fatal pseudomonas infection in burned patients. A clinical, bacteriologic and anatomic study.

Authors:  E R RABIN; C D GRABER; E H VOGEL; R A FINKELSTEIN; W A TUMBUSCH
Journal:  N Engl J Med       Date:  1961-12-21       Impact factor: 91.245

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  Bacterial precipitins in serum of patients with cystic fibrosis.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

8.  A serologic response in human pseudomonas infection.

Authors:  J G Crowder; A White
Journal:  J Lab Clin Med       Date:  1970-01

9.  Gentamicin in the treatment of severe, hospital-acquired gram-negative infections.

Authors:  L S Young; D B Louria; D Armstrong
Journal:  Trans N Y Acad Sci       Date:  1967-03

10.  Serologic types of Pseudomonas aeruginosa based on heat-stable O antigens: correlation of Habs' (European) and Verder and Evans' (North American) classifications.

Authors:  T F Muraschi; D M Bolles; C Moczulski; M Lindsay
Journal:  J Infect Dis       Date:  1966-02       Impact factor: 5.226

View more
  9 in total

1.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

2.  Cross-protection by Pseudomonas aeruginosa polysaccharides.

Authors:  G B Pier
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

3.  Precipitating antibody against core glycolipid of Enterobacteriaceae.

Authors:  L S Young; P R Stevens
Journal:  Experientia       Date:  1974-02-15

4.  Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.

Authors:  R J Jones; E A Roe
Journal:  Br J Exp Pathol       Date:  1975-02

5.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli.

Authors:  J B Goldberg; K Hatano; G S Meluleni; G B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

8.  Evaluation of three serological tests for detection of antibody to Pseudomonas aeruginosa in human sera.

Authors:  T L Pitt; H C Todd; C A Mackintosh; S W Im
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

9.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.